For a Healthier Tomorrow: Prioritising Early Detection Through Smart Screening
In line with our participation in NDP 2023, the Ascle Healthcare team is proud to champion preventive healthcare by raising awareness about gut health and the importance of early cancer detection.
Together with our partner, MiRXES, we are introducing GASTROClear™—the world’s first molecular blood test approved for the early detection of gastric (stomach) cancer. This groundbreaking test identifies gastric cancer biomarkers through a single blood draw, offering a non-invasive way to assess cancer risk before symptoms appear.
Why Early Detection Matters
Gastric cancer is one of the most silent yet deadly diseases, often progressing without noticeable symptoms until it reaches an advanced stage. In 2018 alone, it was responsible for over 783,000 deaths worldwide. At later stages, the five-year survival rate drops significantly, making early screening a critical factor in saving lives.
How GASTROClear™ Works
Developed by clinicians and scientists from NUHS and MiRXES, GASTROClear™ uses microRNA (miRNA) markers in the blood to assess an individual’s risk level. The test delivers a report categorised into Low, Intermediate, or High Risk. Those identified as High Risk will be referred for a gastroscopy for clinical confirmation.
Who Should Get Screened?
You may be at risk for stomach cancer if you:
- Are over 40 years old
- Have a family history of stomach cancer
- Have a history of gastritis, H. pylori infection, or other stomach illnesses
- Smoke, drink alcohol frequently, or consume a diet high in preserved or smoked foods
Taking a proactive approach through regular screening is essential—especially when the disease shows no signs in its early stages.
Together with MiRXES, we aim to make early detection more accessible and change lives through education and innovation.
▶️ Learn more about GASTROClear™
🔗 Visit: gastroclear.mirxes.com